CA3242755A1 - Deuterated organic compounds and uses thereof - Google Patents
Deuterated organic compounds and uses thereofInfo
- Publication number
- CA3242755A1 CA3242755A1 CA3242755A CA3242755A CA3242755A1 CA 3242755 A1 CA3242755 A1 CA 3242755A1 CA 3242755 A CA3242755 A CA 3242755A CA 3242755 A CA3242755 A CA 3242755A CA 3242755 A1 CA3242755 A1 CA 3242755A1
- Authority
- CA
- Canada
- Prior art keywords
- deteriorative
- organic compounds
- compounds
- formula
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263296137P | 2022-01-03 | 2022-01-03 | |
| US63/296,137 | 2022-01-03 | ||
| US202263314466P | 2022-02-27 | 2022-02-27 | |
| US63/314,466 | 2022-02-27 | ||
| US202263345002P | 2022-05-23 | 2022-05-23 | |
| US63/345,002 | 2022-05-23 | ||
| US202263394565P | 2022-08-02 | 2022-08-02 | |
| US63/394,565 | 2022-08-02 | ||
| US202263384988P | 2022-11-25 | 2022-11-25 | |
| US63/384,988 | 2022-11-25 | ||
| PCT/US2023/010055 WO2023130119A1 (en) | 2022-01-03 | 2023-01-03 | Deuterated organic compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3242755A1 true CA3242755A1 (en) | 2023-07-06 |
Family
ID=87000385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3242755A Pending CA3242755A1 (en) | 2022-01-03 | 2023-01-03 | Deuterated organic compounds and uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12606523B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4460292A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025501411A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240132477A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023204433B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3242755A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL313999A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024008371A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202333671A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023130119A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025010255A2 (en) | 2023-07-02 | 2025-01-09 | Engrail Therapeutics, Inc. | Deuterated organic compounds and uses thereof |
| WO2026011157A1 (en) | 2024-07-05 | 2026-01-08 | Engrail Therapeutics, Inc. | Crystalline forms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4197243A (en) * | 1975-04-02 | 1980-04-08 | Yamanouchi Pharmaceutical Co., Ltd. | N-1-Benzyl-3-pyrrolidinyl-4-dimethylamino benzamide derivatives |
| US4210660A (en) | 1978-12-20 | 1980-07-01 | Yamanouchi Pharmaceutical Co., Ltd. | Benzamide derivatives |
| TW212139B (cg-RX-API-DMAC10.html) | 1991-04-15 | 1993-09-01 | Yamanouchi Pharma Co Ltd | |
| KR100355130B1 (ko) | 1992-09-18 | 2003-01-30 | 야마노우치세이야쿠 가부시키가이샤 | 하이드로겔서방성정제 |
| US5705498A (en) | 1992-11-05 | 1998-01-06 | Smithkline Beecham Plc. | Piperidine derivatives as 5-HT4 receptor antagonists |
| US6872405B2 (en) | 2001-05-10 | 2005-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Quick-disintegrating tablet in buccal cavity and manufacturing method thereof |
| KR102967223B1 (ko) | 2013-12-03 | 2026-05-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| CN104744333A (zh) | 2013-12-26 | 2015-07-01 | 张云 | 一种奈莫必利的生产方法 |
| US20190343827A1 (en) | 2018-05-08 | 2019-11-14 | Izumi Technology, Llc | Deuterated analogs of tariquidar |
| WO2020176597A1 (en) | 2019-02-27 | 2020-09-03 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| US20210017160A1 (en) | 2019-07-16 | 2021-01-21 | Cyclerion Therapeutics, Inc. | DEUTERATED sGC STIMULATORS |
| JP2025501410A (ja) | 2022-01-03 | 2025-01-17 | エングレイル・セラピューティクス・インコーポレイテッド | 重水素化有機化合物およびその使用 |
| WO2025010255A2 (en) | 2023-07-02 | 2025-01-09 | Engrail Therapeutics, Inc. | Deuterated organic compounds and uses thereof |
-
2023
- 2023-01-03 WO PCT/US2023/010055 patent/WO2023130119A1/en not_active Ceased
- 2023-01-03 AU AU2023204433A patent/AU2023204433B2/en active Active
- 2023-01-03 KR KR1020247025930A patent/KR20240132477A/ko active Pending
- 2023-01-03 TW TW112100105A patent/TW202333671A/zh unknown
- 2023-01-03 JP JP2024561731A patent/JP2025501411A/ja active Pending
- 2023-01-03 IL IL313999A patent/IL313999A/en unknown
- 2023-01-03 CA CA3242755A patent/CA3242755A1/en active Pending
- 2023-01-03 EP EP23735189.5A patent/EP4460292A4/en active Pending
-
2024
- 2024-07-02 MX MX2024008371A patent/MX2024008371A/es unknown
- 2024-07-03 US US18/763,819 patent/US12606523B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20250011280A1 (en) | 2025-01-09 |
| KR20240132477A (ko) | 2024-09-03 |
| AU2023204433A1 (en) | 2024-07-18 |
| WO2023130119A1 (en) | 2023-07-06 |
| MX2024008371A (es) | 2024-12-06 |
| IL313999A (en) | 2024-08-01 |
| AU2023204433B2 (en) | 2026-07-30 |
| EP4460292A4 (en) | 2025-07-16 |
| JP2025501411A (ja) | 2025-01-17 |
| TW202333671A (zh) | 2023-09-01 |
| EP4460292A1 (en) | 2024-11-13 |
| US12606523B2 (en) | 2026-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022019991A2 (pt) | Compostos, composição farmacêutica compreendendo o mesmo, e usos dos mesmos | |
| BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| MA32941B1 (fr) | Composes organiques | |
| EP3362445A4 (en) | OXADIAZOLAMINE DERIVATIVE COMPOUNDS AS HISTONDEACETYLASE-6 INHIBITORS AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| EA201891622A1 (ru) | Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их | |
| GEAP202215303A (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
| MY142589A (en) | Benzimidazole derivatives : preparation and pharmaceutical applications | |
| JOP20220085A1 (ar) | مركبات أريل ميثيلين حلقية غير متجانسة على هيئة حاصرات قناة بوتاسيوم Kv1.3 بجين شاكر | |
| CA3242751A1 (en) | Deuterated organic compounds and uses thereof | |
| WO2025010259A3 (en) | Deuterated organic compounds and uses thereof | |
| DE602005008065D1 (de) | Von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs | |
| BRPI0612125A2 (pt) | compostos da fórmula (i), processo para a fabricação destes, composto da fórmula iiia, composições farmacêuticas, método para o tratamento e/ou profilaxia de doenças associadas à modulação dos receptores cb1 e uso de compostos | |
| DE602005023755D1 (de) | Indolonderivate, verfahren zu deren herstellung und deren anwendungen | |
| SA522431304B1 (ar) | عمليات تحضير اللاسميديتان وملح الأسيتات منه | |
| MX2024008371A (es) | Compuestos organicos deuterados y usos de los mismos | |
| EP3694330A4 (en) | INDAZOLYL-SPIRO [2.2] PENTANCARBONITRIL DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES | |
| EP4599892A3 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| ATE424384T1 (de) | Imidazolderivate, verfahren zu deren herstellung und deren anwendungen | |
| WO2020024017A9 (en) | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof | |
| EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
| EP3999045A4 (en) | NLRP3 INFLAMMA SUMMER INHIBITOR COMPOUNDS AND COMPOSITIONS AND USES THEREOF | |
| BRPI0507120A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização | |
| BRPI0508177A (pt) | composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação | |
| NO20082848L (no) | Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre | |
| MA41174B1 (fr) | Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC ASSIGNED Effective date: 20240702 Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC REMOVED Effective date: 20240702 Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: FIRST IPC ASSIGNED Effective date: 20240702 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240703 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240703 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241217 |